GADD45B and Parkinson disease: However, Gadd45b could be a potential target in countering dopamine precursor 3,4-dihydroxyphenyl-L-alanine (L-DOPA)-induced dyskinesia (LID) Parkinson’s disease (Park et al., 2016).